8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

November 28, 2005

HALOZYME THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Nevada	000-49616	88-0488686
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

11588 Sorrento Valley Road, Suite 17, San Diego, California	92121
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (858) 794-8889

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

TABLE OF CONTENTS

	Item 7.01 Regulation FD Disclosure.
	Item 9.01 Financial Statements and Exhibits.
SIGNATURES
EXHIBIT 99.1

Item 7.01 Regulation FD Disclosure.

     Attached hereto as Exhibit 99.1, which is incorporated herein by reference, is a copy of certain slides used by the Company in making investor presentations and that are expected to be used in subsequent presentations to interested parties, including analysts and stockholders.

     This information is being furnished pursuant to Item 7.01 of this Report and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by Halozyme Therapeutics, Inc. under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference. This Report will not be deemed an admission as to the materiality of any information in this Report that is being disclosed pursuant to Regulation FD.

     Please refer to page 2 of Exhibit 99.1 for a discussion of certain forward-looking statements included therein and the risks and uncertainties related thereto.

Item 9.01 Financial Statements and Exhibits.

(c)   Exhibits.

Exhibit No.	Description
99.1	Halozyme Therapeutics, Inc. Investor Presentation dated November 2005.

SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Halozyme Therapeutics, Inc.
November 28, 2005	By:	/s/ David A. Ramsay
		David A. Ramsay
		Secretary and Chief Financial Officer

EX-99.1

EXHIBIT 99.1

Company Overview November 2005 Jonathan Lim, MD President and CEO

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. All statements made in this presentation that are not statements of historical fact constitute forward-looking statements. The matters referred to in forward-looking statements could be affected by the risks and uncertainties of the Company's business. Such risks inherent to the Company's business will be described in the Company's filings, when they occur, with the Securities and Exchange Commission, as well as in its press releases. The Company's actual results may differ materially from those expressed in or indicated by such forward-looking statements. Safe Harbor

HYLENEX drug product targeting $300M+ market, partnered with Baxter, and FDA response to NDA pending Product portfolio is BROAD and DEEP Same enzyme formulated with marketed injectable drugs to improve their performance in approved indications (e.g., ENHANZED anti-TNF-alpha) Same enzyme delivered on its own or with marketed drugs to address new clinical indications for large markets with unmet medical needs (e.g., Chemophase) Management team and commercial infrastructure in place with first enzyme product already launched worldwide Investment Highlights

San Diego-based company, incorporated in 1998 Listed on American Stock Exchange (ticker: HTI) Cash position at end of Q2 2005 - $10.1 million Market capitalization - $94 million as of 10/18/05 50 million shares outstanding Halozyme Therapeutics, Inc.

Product Target indication(s) HYLENEX* Ophthalmic anesthesia, drug & fluid infusion Chemophase(tm) Bladder cancer rHuPH20 IV Oncology, neurology, cardiology Enhanzed products Anti-TNF-alpha for RA, IFN-beta for MS HTI-101; HTI-401 Oncology, inflam- mation; neurology Research Pre- clinical Phase 1 & 2 Phase 3 In registr- ation Marketed product Development status NDA filed IND filed Product Pipeline Cumulase(tm) In vitro fertilization Product launched in US, EU, Japan * HYLENEX is a registered trademark of Baxter International, Inc.

Product Indications U.S. Market HYLENEX Ophthalmic anesthesia $50 million HYLENEX Drug and fluid infusion $200 - 300 million Chemophase Superficial bladder cancer $600 - 700 million rHuPH20 IV Oncology, neurology, cardiology >$1 billion Market Opportunities

Focus of presentation Multi-Horizon Growth Strategy HYLENEX Enhanzed drug products Chemophase rHuPH20 IV for systemic indications HTI-101, HTI-401 HTI Value Horizon 1 Commercialize late stage products with low development risk and high upside Horizon 2 Develop products serving unmet medical needs and large markets Horizon 3 Develop other product candidates in pipeline 4 8 12+ Potential time to market (years) Primary product focus 0

Horizon 1 Opportunities HYLENEX Enhanzed drug products Horizon 1 Commercialize late stage products with low development risk and high upside Horizon 2 Develop products serving unmet medical needs and large markets Horizon 3 Develop other product candidates in pipeline 4 8 12+ 0

Proposed labeled indications* "For use as an adjunct to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; as an adjunct in subcutaneous urography; for improving the resorption of radiopaque agents." Drug & fluid infusion Indication Description Enhances diffusion of anesthesia during ophthalmic surgery 50+ years clinical validation from Wyeth's Wydase(r), used in ~750,000 procedures in 1999** * DESI review findings published in the Federal Register (September 23, 1970; 35(185):14800-1) ** Removed from market in 2001 due to manufacturing issues (AAO; Roundtable discussion of Wydase Shortage, March 2005) Enhances absorption and dispersion of other injected drugs and fluids (hypodermoclysis) Ophthalmic anesthesia HYLENEX (NDA pending)

Local Anesthetic + HYLENEX HYLENEX: For Ophthalmic Anesthesia HA

Eye Safely Immobilized for Cataract Surgery

U.S. Ophthalmic Anesthesia Market HYLENEX targets 1.2 million cataract surgeries utilizing local injection anesthesia Relevant market for Hyaluronidase 100% = 2.8 million cataract surgery procedures Topical anesthesia Local injection HYLENEX: For Ophthalmic Anesthesia Source: WHO; Optistock.com; SG Cowen; Alcon; ASCRS Survey (2003); HTI analysis

Background IV access difficult to establish and maintain, especially at home Hospital admission often due to need for systemic access (e.g., antibiotics, fluids) Subcutaneous (SC) drug and fluid infusion with HYLENEX is a compelling alternative to IV access HYLENEX: For Drug and Fluid Infusion Source: UpToDate, 2005; American Family Physician, 2001

Control 2MIN rHuPH20 300ul/Min PBS HYLENEX: For Drug and Fluid Infusion

Saline + rHuPH20 Saline HYLENEX: For Drug and Fluid Infusion

Starting a subcutaneous infusion site is easy for the caregiver . . . .. . . and convenient for the patient, even at home Can use butterfly needle Can insert SC anywhere in the body (no misses) Especially useful for: Patient with poor venous access Agitated patients who repeatedly remove their IV lines Facilities without continuous availability of skilled providers to insert IVs, including home HYLENEX: Benefits of SC Infusion

Source: National Home and Hospice Care Survey, 2000; The National Nursing Home Survey, 1999 Summary SC Infusion Market Opportunity in Hospices and Nursing Homes Hospices Number of hospices: 2,273 Number of current patients: 106,000 Average length of service: 47 days Nursing Homes Number of nursing homes: 18,000 Number of current patients: 1.6 million Average length of stay (range): 272 to 892 days

Baxter to market, distribute, and sell HYLENEX in US and Puerto Rico Baxter and Halozyme are equal partners in commercialization of HYLENEX Initial targets are ophthalmic anesthesia and drug & fluid infusion indications Partners may mutually agree to pursue other dosage forms and indications HYLENEX: Sales & Marketing Deal with Baxter

Decrease pain and tissue distortion upon injection Reduce adverse injection site reactions Change route of administration (e.g., IV to SC) Convenience & compliance Extend product lifecycle of drugs coming off patent Provide differentiation for multi-sourced drugs Enable inpatient drugs to be injected at home Economic benefits Enhanze(tm) Technology Value Proposition for drug dispersion Deliver more drug to intended targets Allow drug to work faster Increase volume of drug at each injection Efficacy Enhanzed Drug Products: rHuPH20 with Injectable Drugs

0.0E+00 2.0E+05 4.0E+05 6.0E+05 8.0E+05 1.0E+06 1.2E+06 1.4E+06 1.6E+06 1.8E+06 2.0E+06 0 10 20 30 40 50 60 70 80 90 100 110 120 130 Time (Hours) Serum Antibody Levels (I-125Counts/ml) in rats IgG 10mg/kg local Bioavailability =59 +/- 7% Enhanzed Commercial Anti- Rheumatic Monoclonal Antibody IgG 10mg/kg local + rHuPH20 Bioavailability =94 +/- 7% Bioavailability =100% IgG 10mg/kg IV

0.0E+00 5.0E+04 1.0E+05 1.5E+05 2.0E+05 2.5E+05 3.0E+05 3.5E+05 4.0E+05 0 10 20 30 40 50 Time (Hours) Local Serum Interferon Levels (I-125 Counts/ml) in rats Bioavailability =61% Local +rHuPH20 Intravenous Local Local +rHuPH20 Enhanzed Commercial Interferon

Add value to partners 1 Develop proprietary products 2 * DESI review findings published in the Federal Register (Sept. 23, 1970; 35(185):14800-1) Generate clinical data for specific products to help Halozyme and potential business partners make better decisions: Taking The Next Step: Product-Focused Strategy Conduct low cost proof of concept (POC) clinical studies to generate PK/tolerability data Use the data to achieve two objectives Product-specific clinical data more powerful than pre-clinical data Lower cost, faster time to market for Enhanzed drug products Proposed labeled indications* "For use as an adjunct to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; as an adjunct in subcutaneous urography; for improving the resorption of radiopaque agents."

2004 US Sales for Drug Class Anti-TNF-alpha drug for rheumatoid arthritis $4.2 billion IFN-beta drug for multiple sclerosis $1.7 billion Currently marketed macromolecule >$1 billion Currently marketed small molecule ~$1 billion Total ~$8 billion Source: IMS (2004); HTI analysis Target Currently Marketed Compound Initial Commercial Targets for Clinical POC Studies Add value to partners 1 Develop proprietary products 2

Horizon 2 Opportunities Horizon 1 Commercialize late stage products with low development risk and high upside Horizon 2 Develop products serving unmet medical needs and large markets Horizon 3 Develop other product candidates in pipeline 4 8 12+ 0 Chemophase rHuPH20 IV for systemic indications

Chemophase: For Superficial Bladder Cancer

Chemophase: For Superficial Bladder Cancer

Mitomycin Mitomycin + Bovine PH20 Mean age (range) 62.8 (44-80) 67.3 (49-84) Men/Women 17/11 18/10 Primary tumors 15 16 Recurrent tumors 13 12 Mean Follow Up (range) 21.1 (6-32) 20.2 (6-32) Tumor Recurrence (%) 9/28 (32.1%) 2/28 (7.1%) P<0.05 P<0.05 Source: Maier and Baumgartner, 1989 Randomized Clinical Trial of Bovine PH20 in Bladder Cancer Initiated Chemophase Ph I trial in 4Q05

Penetration of Chemotherapy with Chemophase in Bladder Cancer Chemotherapy alone Chemotherapy with Chemophase

63,210 new cases of urinary bladder cancer in the US1,2 499,199 prevalent cases of urinary bladder cancer3,4 At least 6 treatment cycles of mitomycin and Chemophase Source: 1 American Cancer Society, 2005; 2 ~70% of new cases are "superficial" disease (AUA Bladder Cancer Guidelines Panel, 1999); 3 NCI SEER Cancer Statistics Review, 2002; 4 ~30% recurrence rate of treated patients within 12 months (Southwest Oncology Group Study, 1995) Chemophase, if adopted as first line therapy with mitomycin, would target ~100,000 patient candidates and ~600,000 potential doses/year Chemophase Market Opportunity in Superficial Bladder Cancer

Stroke can cause brain edema leading to further tissue damage and higher mortality Tissue edema is important in multiple disease states, including stroke, myocardial infarction, and oncology 6 hrs post infarct Ischemic stroke in a 61 year old male Systemic rHuPH20: For Ischemic Stroke

Systemic administration of rHuPH20 after experimental infarct improves survival and reduces edema in rodent 28 day ischemic stroke models rHuPH20 versus Saline 2 hrs post infarct (n=40 rats/group) Systemic rHuPH20: For Ischemic Stroke

Hyaluronidases normally cleared from circulation very quickly (T1/2<3 min) PK optimization of rHuPH20 with PEGylation significantly increases T1/2 Improved serum half life of PEG-rHuPH20 also translates into improved survival in rodent models PEG-rHuPH20 Serum PK Analysis PH20 Enzymes 0 10 20 30 40 50 60 70 1 10 100 1000 10000 Animal Testes Hyaluronidase PH20 Time (min) Units / ml activity plasma PEG-PH20 rHuPH20 versus Saline 2 hrs post infarct (n=40 rats/group) Systemic rHuPH20: For Ischemic Stroke

Completed Cumulase CE Mark received, 4Q04 HYLENEX NDA filed, priority review, 1Q05 Cumulase 510(k) cleared and product launched, 1H05 Chemophase IND filed, 2Q05; initiated Phase I trial, 4Q05 2005 - 2006 Milestones* * Forward-looking statement Upcoming FDA response to HYLENEX NDA pending Initiate Chemophase Phase I/IIa trial, 1H06 Initiate POC clinical study for hypodermoclysis, 1H06 Initiate POC clinical studies for initial commercial targets, 2006

Robust pipeline with first product selling, second product NDA pending, third product in the clinic, and several POC studies of proprietary and partnerable projects starting next year Attractive business model effectively balancing risk and reward to drive shareholder value over the long term Consistent delivery of milestones by full management team with demonstrated track record of success Investment Summary